Polar Asset Management Partners Inc. Cuts Stock Holdings in AngioDynamics, Inc. $ANGO

Key Points

• Polar Asset Management Partners Inc. reduced its stake in AngioDynamics by 65.2%, holding 64,537 shares worth approximately $606,000 after selling 120,708 shares in the first quarter.
• AngioDynamics reported a quarterly earnings of ($0.03) EPS, exceeding analyst expectations, and a 13.0% increase in revenue year-over-year.
• Analysts have a consensus "Buy" rating for AngioDynamics, with target prices ranging from $15.00 to $24.00, indicating positive market sentiment for the company's growth potential.

Polar Asset Management Partners Inc. trimmed its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 65.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 64,537 shares of the medical instruments supplier's stock after selling 120,708 shares during the quarter. Polar Asset Management Partners Inc. owned 0.16% of AngioDynamics worth $606,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Armistice Capital LLC grew its position in AngioDynamics by 140.1% during the first quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier's stock worth $19,663,000 after buying an additional 1,222,000 shares during the period. Nuveen LLC acquired a new position in AngioDynamics during the first quarter worth about $10,803,000. Bastion Asset Management Inc. acquired a new position in AngioDynamics during the first quarter worth about $6,601,000. AIGH Capital Management LLC acquired a new position in AngioDynamics during the first quarter worth about $4,455,000. Finally, Paradigm Capital Management Inc. NY acquired a new position in AngioDynamics during the fourth quarter worth about $3,701,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Price Performance

NASDAQ:ANGO traded down $0.26 during trading hours on Friday, reaching $10.71. 300,484 shares of the company were exchanged, compared to its average volume of 608,724. The firm has a market cap of $434.99 million, a price-to-earnings ratio of -12.92 and a beta of 0.64. AngioDynamics, Inc. has a 52-week low of $5.83 and a 52-week high of $13.50. The stock has a 50 day simple moving average of $9.39 and a 200 day simple moving average of $9.58.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.09. The company had revenue of $80.16 million for the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. AngioDynamics's revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.06) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. On average, analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ANGO shares. Wall Street Zen upgraded shares of AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Canaccord Genuity Group increased their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. Lake Street Capital assumed coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of AngioDynamics in a research note on Wednesday, July 16th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, AngioDynamics has a consensus rating of "Buy" and a consensus target price of $19.00.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.